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Introduction
Helicobacter species colonise the human gastrointestinal and
hepatobiliary tract, usually resulting in chronic infection
coupled with an inflammatory host response. This
colonisation is associated with a variety of gastrointestinal
and hepatobiliary diseases.1 The enterohepatic helicobacters
such as Helicobacter hepaticus and H. bilis, first recognised in
laboratory rodents, have been considered a component of
the normal flora. H. hepaticus colonises the lower
gastrointestinal tract, including the caecum, colon and
hepatobiliary system of mice and causes chronic active
hepatitis and typhlocolitis in immunocompetent mice and
can lead to liver carcinoma in male mice of susceptible
strains.2–5 H. bilis was also identified in inbred mice with
chronic hepatitis.6 Patients with chronic liver disease have
been reported to have significantly higher levels of antibody
to H. bilis and H. hepaticus compared to healthy subjects.7
These urease-producing bacteria may induce stone
formation by hydrolysing urea into ammonia that increases
the pH and favours precipitation of salts that lead to
subsequent stone formation.8,9 It has also been demonstrated
that cholesterol gallstone-prone C57L/J mice rarely develop
gallstones unless they are infected with certain
cholelithogenic enterohepatic Helicobacter species.10 In a
previous study, all four urease-positive Helicobacter species
(H. hepaticus, H. bilis, H. pylori and H. mustelae) were shown
to be capable of precipitating calcium.11 This suggests that
urease-positive Helicobacter species that are able to survive in
or colonise the bile ducts may induce the formation of
gallstones, both directly via their urease activity or indirectly
via the immune response.11 H. pylori has also been shown to
colonise areas of gastric metaplasia in the gall bladder,
producing histological changes similar to those seen in the
gastric mucosa.12 Isolation of H. pylori DNA from gallstones
further supports its presence in the gall bladder.12 
Helicobacter species have been detected in patients with
biliary tract cancer significantly more frequently than in
controls.13–15 There are reports that biliary Helicobacter
colonisation is frequent in countries with a high incidence of
gall bladder carcinoma, the highest incidence rates in this
region being reported for women in Delhi, India
(21.5/100,000), and in Karachi, Pakistan (13.8/100,000).16 In a
previous study, the incidence of gallstones was determined
in cases of carcinoma of the gall bladder. In this series, 93%
of patients had gallstones (85% were female, age range:
27–65 years).17 A recent study in Karachi looked at the
frequency of biliary infection associated with cholelithiasis.
Results showed that a total of 36% had bile culture positive
for Escherichia coli (17%) Klebsiella (9%), Pseudomonas (6%),
Staphylococcus aureus (2%), Salmonella (1%) and Bacteroides
fragilis (1%).18 However, H. pylori also has a high prevalence
in the local population.19
The prevalence of H. pylori in bile and the gall bladder has
not been examined previously in patients with gall bladder
disorders in Pakistan. Therefore, this study aims to
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ABSTRACT
Helicobacter species colonise the biliary tract and therefore
this study explores the relationship between of Helicobacter
pylori and cholecystitis. Bile and gall bladder tissue samples
were obtained from 144 patients who underwent
cholecystectomy. Of these, 89 had chronic cholecystitis
with cholelithiasis, 44 had gall bladder carcinoma and 11
had gall bladder polyps. Histopathology examination
included special staining and immunohistochemistry
(IHC), while Helicobacter species (H. pylori, H. bilis and 
H. hepaticus) were detected by the polymerase chain
reaction (PCR). Sequencing and BLAST query of PCR
products was undertaken and samples were considered to
contain H. pylori if both PCR and IHC were positive.
Immunohistochemistry for H. pylori was positive in 22
(25%) cases compared to five (9%) in the control group
(P=0.02). Testing (PCR) for 16S rDNA was positive in 
23 (26%) cases compared to six (11%) controls (P=0.03).
Negative PCR results were obtained for H. bilis and 
H. hepaticus. Twenty-four (89%) were positive by both 16S
rDNA PCR and IHC for H. pylori (P<0.001). Both PCR for
16S rDNA and IHC were positive in 21 (24%) cases
compared to five (9%) controls (P=0.03). Sequencing of 16S
rRNA and glmM PCR products were consistent with 
H. pylori. In conclusion, H. pylori DNA was demonstrated
in cases of chronic cholecystitis and gall bladder carcinoma
associated with cholelithiasis, but this association requires
further study.
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investigate the frequency of H. pylori in gall bladder tissue
and bile from patients who underwent cholecystectomy for
cholelithiasis, and compare them with those having
cholecystectomy for gall bladder polyps (GBP) and
carcinoma (GBC).
Materials and Methods
One hundred and forty-four patients undergoing
cholecystectomy were enrolled on the study between
January 2008 and December 2009 (101 [70%] females, 43
[30%] males; mean age: 49±14 [range 18–84]). All presented
with recurrent upper right abdominal pain. Eighty-nine
patients who had cholecystectomy for cholelithiasis
associated with chronic cholecystitis were included in the
study group. The control group comprised 55 patients who
underwent cholecystectomy, 11 for GBP and 44 for GBC. 
Of the GBC patients, 25% (11/44) also had gallstones. 
None of the GBP patients had stones. The study was
approved by the institutional ethics review committee. 
Histopathology examination included haematoxylin and
eosin (H&E), Giemsa and Warthin-Starry staining and
immunohistochemistry (IHC). Gall bladder tissue and bile
were used to extract DNA for PCR of the H. pylori 16S
ribosomal DNA (rDNA) and phosphoglucosamine mutase
(glmM) gene. If positive, these were further evaluated for
cytotoxin-associated gene (cagA) and vacuolating cytotoxin-
A (vacA) gene alleles. Diagnosis of H. pylori infection was
established when both PCR and IHC were positive. To detect
H. bilis and H. hepaticus, specific primer sets for 16S ribosomal
RNA (rRNA) sequences of H. bilis and H. hepaticus were used. 
Immunohistochemistry staining for H. pylori was
performed using streptavidin peroxidase (SP). Anti-H. pylori
antibody (Dako) was diluted (1 in 10), and phosphate-
buffered saline (PBS) was used as blank control, normal
blood serum as a negative control, and sections of gastric
mucosa containing H. pylori as the positive control. 
DNA extraction
Extraction of DNA from bile and gall bladder tissue was
performed as described previously.20 Briefly, 450 µL bile was
diluted with an equal volume of PBS (pH 8) and centrifuged
at 14 000 xg for 20 min. The supernatant was discarded and
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Gene Sequence (5’ to 3’) Reaction conditions Amplicon size (bp) Position
16S rRNA C97 5’-GCT ATG ACG GGT ATC C-3’ 94˚C for 5 min 400 276–291
C 98 5’-GAT TTT ACC CCT ACA CCA-3’ 94˚C for 1 min 681–698
55˚C for 1 min
72˚C for 90 sec (35 cycles)
72˚C for 7 min
glmM GGATAAGCTTTTAGGGGTGTTAGGGG 94˚C for 1 min 296
GCTTACTTTCTAACACTAACGCGC 56˚C for 1 min
72˚C for 1 min (35 cycles)
72˚C for 5 min
cagA 94˚C for 5 min 297 1751–2048
D008 ATAATGCTAAATTAGACAACTTGAGCGA 94˚C for 1 min
R008 TTAGAATAATCAACAAACATCACGCCAT 55˚C for 1 min
72˚C for 1.5 min (35 cycles)
72˚C for 5 min
vacA 95˚C for 5 min 290 2741–3030
M1 95˚C for 1 min
VA3-F GGTCAAAATGCGGTCATGG 52˚C for 1 min
VA3-R CCATTGGTACCTGTAGAAAC 72˚C for 1 min (35 cycles)
M2 72˚C for 5 min
VA4-F GGAGCCCCAGGAAACATTG 352 976–1327
VA4-R CATAACTAGCGCCTTGCAC
S1a
SS1-F GTCAGCATCACACCGCAAC 190 866–1055
VA1-R CTGCTTGAATGCGCCAAAC
S1b
SS3-F AGCGCCATACCGCAAGAG 187
VA1-R CTGCTTGAATGCGCCAAAC
H. bilis 94˚C for 5 min 418
F CAGAACTGCATTTGAAACTAC 94˚C for 1 min
R AAGCTCTGGCAAGCCAGC 55˚C for 1 min
72˚C for 1 min (35 cycles)
72˚C for 5 min
H. hepaticus 94˚C for 5 min 405
F GAAACTGTTACTCTG 94˚C for 1 min
R TCAAGCTCCCCGAAGGG 55˚C for 1 min
72˚C for 1 min (35 cycles)
72˚C for 5 min
Table 1. Oligonucleotide primers used to amplify the 16S rRNA and Helicobacter pylori-specific genes.
the pellet was mixed with 250 µL PBS and recentrifuged. Bile
sample pellets were incubated with lysis buffer (50 mmol/L
Tris HCl [pH 7.2], 1 mmol/L EDTA, 0.45% sodium dodecyl
sulphate [SDS], 0.45% NP-40 and 100 mg/mL protease K) for
20 h at 56˚C and extracted (x2) with phenol–chloroform
(equal volumes). After another extraction with chloroform,
the DNA was precipitated with absolute ethanol and
dissolved in TE buffer (10 mmol/L Tris [pH 8] and 1 mmol/L
EDTA). 
Extraction of DNA from gall bladder tissue was performed
as described previously.21 Gall bladder tissue (50 mg) was
homogenised to uniformity in 400 µL sterile water and
centrifuged at 8000 xg for 10 min. Then, 400 µL lysis buffer
(100 mmol/L NaCl, 10 mmol/L Tris-HCl [pH 8], 25 mmol/L
EDTA, 0.5% SDS) and 10 µL proteinase K (10 mg/mL) were
added. Incubation was carried out at 56˚C for 20 h, and
proteinase K was inactivated by boiling for 10 min. This was
followed by phenol-chloroform extraction and ethanol
precipitation. The resulting pellet was allowed to dissolve in
35 µL TE buffer (10 mmol/L Tris-HCl [pH 7.4] and 0.1 mmol/L
EDTA [pH 8]) for 20 h at 37˚C. Samples were stored at –20˚C
before PCR amplification was performed. DNA content and
purity was determined by measuring absorbance at 260 nm
and 280 nm using a spectrophotometer (Beckman DU-600,
USA). 
PCR amplification 
Samples were amplified by Helicobacter genus-specific 16S
rRNA primers. The forward (C97) and reverse (C98) primers
amplified a product of approximately 400 bp.21 Samples
generating a positive result were subsequently analysed
with eight different sets of primers. Two specific primer sets
were used to detect H. bilis and H. hepaticus 16S rRNA
sequences previously described.22 The other six specific
primers used were to look for the glmM and vacA alleles 
(e.g., s1a, s1b, s1m1 and s1m2, and cagA genes),23,24 which
encode potential virulence factors in H. pylori. Nucleotide
primer sequences and PCR conditions are shown in Table 1.
The amplified products were analysed on 2% (w/v) agarose
gel stained with ethidium bromide and observed under
short-wavelength ultraviolet light.
Sequence analyses 
Amplicons were purified from the agarose gel by a DNA
extraction kit (Roche, Indianapolis, Indiana, USA). Three
amplicons from the gall bladder were sequenced to verify
that they were H. pylori 16S rRNA and glmM genes.
Sequence analysis was performed (Macrogen, Seoul, South
Korea) using primers for 16S rRNA and glmM genes.
Sequence comparison was carried out using the BLAST
program and the GenBank database. 
Statistical analysis
The Statistical Package for Social Science (SPSS Release 16,
standard version) was used for data analysis. Descriptive
analysis was performed for demographic and clinical features.
Results were presented as mean±SD for quantitative
variables and number (percentage) for qualitative variables.
Univariate analysis was performed using the independent
sample t-test, and Pearson's χ2 test and Fisher’s Exact test were
used where appropriate. P<0.05 was considered statistically
significant. The kappa (κ) test was performed to assess
agreement between two methods of testing.
Results
Histological examination for H. pylori proved inconclusive
by H&E, Giemsa and Warthin-Starry staining.
Immunohistochemistry demonstrated H. pylori in 25%
(22/89) of the case specimens and in 9% (5/55) of the controls
(P=0.02; Table 2).
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Cholecystitis with cholelithiasis Control group P value
(n=89) (n=55)
Polymerase chain reaction
16S rDNA Positive 23 (26) 6 (11) 0.03
Negative 66 (74) 49 (89)
glmM Positive 21 (24) 5 (9) 0.03
Negative 68 (76) 50 (91)
cagA Positive 4 (5) 0 (0) 0.30
Negative 85 (95) 55 (100)
VacA s1am1 Positive 4 (5) 0 (0) 0.30
Negative 85 (95) 55 (100)
VacA s1am1 Positive 8 (9) 3 (6) 0.53
Negative 81 (91) 52 (94)
Immunohistochemistry Positive 22 (25) 5 (9) 0.02
Negative 67 (75) 50 (91)
Criteria used for the confirmation of H. pylori infection
16S rRNA PCR+ Immunohistochemistry Positive 21 (24) 5 (9) 0.03
Negative 68 (76) 50 (91)
PCR glmM+ immunohistochemistry Positive 21 (24) 5 (9) 0.03
Negative 68 (76) 50 (91)
Univariate analysis was performed by using the independent sample t-test, Pearson χ2 test and Fisher Exact test were also used as appropriate. 
P<0.05 was considered statistically significant. Percentages shown in parentheses.
Table 2. Diagnostic yield of various tests in different groups.
Results of PCR amplification of 16S rDNA, glmM, cagA and
vacA in the different groups are shown in Table 2. None of
the samples showed PCR positivity for either H. bilis or 
H. hepaticus. H. pylori 16S rDNA PCR and IHC were both
positive in 24% (21/89) of study cases compared to 9% (5/55)
of the control group (P=0.03; Table 2). The glmM gene PCR
and IHC were also both positive in 24% (21/89) of study
group cases compared to 9% (5/55) of the control group
(P=0.03; Table 2).
There was significant correlation between PCR for 
H. pylori 16S rDNA and IHC, with 20/23 in the study group
positive by both techniques (κ=85%, P<0.001). Both PCR for
16S rDNA and IHC were positive in 21(24%) cases of
cholecystitis associated with gallstones, in no cases of gall
bladder carcinoma without cholelithiasis (P<0.001) and in
5/6 (83%) cases of gall bladder carcinoma with cholelithiasis
(P=0.005; Tables 3a–c).
Three 16S rRNA and glmM gene PCR products 
were selected at random for sequencing. The 16S rRNA 
gene sequences HM596599–HM596601 and glmM gene
sequences GQ334379–GQ334382 produced significant
alignments with NC 008086.1 H. pylori HPAG1, 
NC 000915.1 H. pylori 26695, NC 000921.1 H. pylori J99 
and NC 008229.1.
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Cholecystitis Gall bladder P value
with cholelithiasis carcinoma
(n=89) (n=38)
PCR 
16SrRNA Positive 23 (26) 1 (3) 0.001
Negative 66 (74) 37 (97)
GlmM Positive 21 (10) 0 (0) 0.201
Negative 68 (90) 38 (100)
Immunohistochemistry Positive 22 (25) 0 (0) <0.001
Negative 67 (75) 38 (100)
Univariate analysis was performed by using the independent sample t-test, Pearson χ2 test and Fisher Exact test were also used as appropriate.
P<0.05 was considered statistically significant. Percentages shown in parentheses.
Table 3a. Comparison of cholecystitis with cholelithiasis and gall bladder carcinoma without stones.
Cholecystitis Gall bladder carcinoma P value
with cholelithiasis with stones
(n=89) (n=6)
PCR
16S rRNA Positive 23 (26) 5 (83) 0.008
Negative 66 (74) 1 (17)
glmM Positive 21 (10) 5 (83) 0.005
Negative 68 (90) 1 (17)
Immunohistochemistry Positive 22 (25) 5 (83) 0.007
Negative 67 (75) 1 (17)
Univariate analysis was performed by using the independent sample t-test, Pearson χ2 test and Fisher Exact test were also used as appropriate.
P<0.05 was considered statistically significant. Percentages shown in parentheses.
Table 3b. Comparison of cholecystitis with cholelithiasis and gall bladder carcinoma with stones.
Cholecystitis Gall bladder P value
with cholelithiasis polyp
(n=89) (n=11)
PCR
16S rRNA Positive 23 (26) 0 (0) 0.06
Negative 66 (74) 11 (100)
glmM Positive 21 (24) 0 (0) 0.11
Negative 68 (74) 11 (100)
Immunohistochemistry Positive 22 (23) 0 (0) 0.17
Negative 67 (77) 11 (100)
Univariate analysis was performed by using the independent sample t-test, Pearson χ2 test and Fisher Exact test were also used as appropriate.
P<0.05 was considered statistically significant. Percentages shown in parentheses.
Table 3c. Comparison of cholecystitis with cholelithiasis and gall bladder polyp.
Discussion
This study demonstrated that H. pylori DNA was positive in
24% in a study group comprising patients undergoing
cholecystectomy for cholelithiasis associated with chronic
cholecystitis by PCR and IHC (P=0.03 and P=0.03,
respectively). However, it was not demonstrated in gall
bladder carcinoma without stones or in cases of gall bladder
polyps. 
It is interesting that H&E, Giemsa and Warthin-Starry
stains were inconclusive while IHC results correlated with
PCR findings. This could be explained by the absence of areas
of intestinal metaplasia in the gall bladder mucosa, as
described previously.12 It is also known that after treatment
for chronic active gastritis, H pylori can change shape and
decrease in number, making identification and
differentiation from extracellular debris or mucin difficult. 
In such cases, IHC improves the rate of identification, even
when histological examination and cultures were negative.25,26
This study did not attempt to culture H. pylori from the
bile or the gall bladder as poor culture yield is known to
follow storage of these specimens. Direct culture of clinical
samples would increase the probability of in vitro H. pylori
isolation and identification. 
In a recent study, Chen et al. demonstrated H. pylori in the
gall bladder of patients with chronic cholecystitis,27 in whom
the incidence of bile reflux was significantly higher. H. pylori-
like bacteria were found in 14% of gall bladders using the
Warthin-Starry silver stain and in 7% using IHC.27 They also
demonstrated that in patients with cholecystitis associated
with cholelithiasis there was a high incidence of gastric 
H. pylori infection. Similar results were reported by Caldwell
et al. who studied H. pylori infection rate and gastritis in
patients with chronic calculus cholecystitis before and after
cholecystectomy and found that the duodenogastric reflux
increased after cholecystectomy.28
Bile regurgitation appears to play a role in selecting 
H. pylori that are resistant to bile salts, and, while
aggravating any injury to the gastric mucosa, they are able to
enter the gall bladder from the duodenum.14 Also, low bile
pH has been shown to permit survival of H. pylori.29
Biliary infection, cystic and common bile duct obstruction
and acute cholecystitis have been shown to decrease bile pH,
therefore increasing the likelihood of infection with
Helicobacter species in these diseases.30,31 The implications of
these studies are that H. pylori can resist the effect of bile salts
and survive under basic conditions. 
It is known that increased incidence of hepatobiliary
disease is associated with chronic carriage of Salmonella typhi
and also a high risk of hepatobiliary cancer.32 Whether or not
H. pylori has a similar relationship in patients with chronic
cholecystitis can only be ascertained by a large prospective
study of hepatobiliary disease using appropriate tests for 
H. pylori diagnosis. Thus, currently it is only possible to
conclude that H. pylori is present in the bile and gall bladder
of Pakistani patients with chronic cholecystitis associated
with cholelithiasis and gall bladder carcinoma associated
with cholelithiasis, and is involved in the
immunopathogenesis of gall bladder disorders in some
cases. 5
The authors thank the staff of the Juma Research Laboratory for
help during this study.
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